BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allaire M, Nault J. Advances in management of hepatocellular carcinoma. Current Opinion in Oncology 2017;29:288-95. [DOI: 10.1097/cco.0000000000000378] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu J, Wang P, Han Z, Li T, Yi C, Qiu C, Yang Q, Sun G, Dai L, Shi J, Wang K, Ye H. A novel immunodiagnosis panel for hepatocellular carcinoma based on bioinformatics and the autoantibody-antigen system. Cancer Sci 2021. [PMID: 34821436 DOI: 10.1111/cas.15217] [Reference Citation Analysis]
2 Guo C, Zhou J, Ma B, Wang R, Ge Y, Wang Z, Ji B, Wang W, Zhang J, Wang Z. A Somatic Mutation-Derived LncRNA Signature of Genomic Instability Predicts Prognosis for Patients With Liver Cancer. Front Surg 2021;8:724792. [PMID: 34504866 DOI: 10.3389/fsurg.2021.724792] [Reference Citation Analysis]
3 Guo Y, Luo W, Huang S, Zhao W, Chen H, Ma Y, Ye M, Nie Y, Zhang Y, Huang C, Zhou Q, He X, Chen M. DTYMK Expression Predicts Prognosis and Chemotherapeutic Response and Correlates with Immune Infiltration in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:871-85. [PMID: 34377684 DOI: 10.2147/JHC.S312604] [Reference Citation Analysis]
4 Zhang L, Tao H, Li J, Zhang E, Liang H, Zhang B. Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma. Aging (Albany NY) 2021;13:15990-6008. [PMID: 34049287 DOI: 10.18632/aging.203056] [Reference Citation Analysis]
5 Wehling C, Dill MT, Olkus A, Springfeld C, Chang DH, Naumann P, Longerich T, Kratochwil C, Mehrabi A, Merle U, Pfeiffenberger J, Rupp C, Weiss KH, Mieth M. Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities. J Cancer Res Clin Oncol 2021;147:2471-81. [PMID: 33537908 DOI: 10.1007/s00432-021-03528-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sheng QJ, Tian WY, Dou XG, Zhang C, Li YW, Han C, Fan YX, Lai PP, Ding Y. Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(11): 1255-1271 [PMID: 33250959 DOI: 10.4251/wjgo.v12.i11.1255] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Wang X, Zhang Y, Yang N, He H, Tao X, Kou C, Jiang J. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis. Biomed Res Int 2020;2020:5087643. [PMID: 33015170 DOI: 10.1155/2020/5087643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Tang J, Sui CJ, Wang DF, Lu XY, Luo GJ, Zhao Q, Lian QY, Jeong S, Lin XM, Zhu YJ, Zheng B, Wu R, Wang Q, Liu XL, Liu JF, Xia Q, Wu G, Gu J, Wang HY, Chen L. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. Theranostics 2020;10:5384-97. [PMID: 32373219 DOI: 10.7150/thno.41616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
9 Xie Z, Dang Y, Wu H, He R, Ma J, Peng Z, Rong M, Li Z, Yang J, Jiang Y, Chen G, Yang L. Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma Cells. J Cancer 2020;11:2830-44. [PMID: 32226501 DOI: 10.7150/jca.39328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bao Y, Zhang Y, Lu Y, Guo H, Dong Z, Chen Q, Zhang X, Shen W, Chen W, Wang X. Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition. Int J Biol Sci 2020;16:827-37. [PMID: 32071552 DOI: 10.7150/ijbs.32460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
11 Jiang Z, Mao Z. Astragaloside IV (AS-IV) alleviates the malignant biological behavior of hepatocellular carcinoma via Wnt/β-catenin signaling pathway. RSC Adv 2019;9:35473-82. [PMID: 35528074 DOI: 10.1039/c9ra05933d] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Afifi AM, El-Husseiny AM, Tabashy RH, Khalil MA, El-Houseini ME. Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects. Asian Pac J Cancer Prev 2019;20:3007-13. [PMID: 31653148 DOI: 10.31557/APJCP.2019.20.10.3007] [Reference Citation Analysis]
13 Shao SY, Hu QD, Wang M, Zhao XY, Wu WT, Huang JM, Liang TB. Impact of national Human Development Index on liver cancer outcomes: Transition from 2008 to 2018. World J Gastroenterol 2019; 25(32): 4749-4763 [PMID: 31528099 DOI: 10.3748/wjg.v25.i32.4749] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
14 Wang L, Wang FS. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatol Int 2019;13:521-33. [PMID: 31352593 DOI: 10.1007/s12072-019-09967-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
15 Wang Y, Huang Q, Deng T, Li BH, Ren XQ. Clinical Significance of TRMT6 in Hepatocellular Carcinoma: A Bioinformatics-Based Study. Med Sci Monit 2019;25:3894-901. [PMID: 31128068 DOI: 10.12659/MSM.913556] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Heo YA, Syed YY. Regorafenib: A Review in Hepatocellular Carcinoma. Drugs 2018;78:951-8. [PMID: 29915898 DOI: 10.1007/s40265-018-0932-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
17 Dong JJ, Ying L, Shi KQ. Expression of the Wnt ligands gene family and its relationship to prognosis in hepatocellular carcinoma. Cancer Cell Int 2019;19:34. [PMID: 30814912 DOI: 10.1186/s12935-019-0743-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Ni JY, Liu SS, Sun HL, Wang WD, Zhong ZL, Hou SN, Chen YT, Xu LF. Transcatheter hepatic arterial infusion chemotherapy vs sorafenib in the treatment of patients with hepatocellular carcinoma of Barcelona Clinic Liver Cancer stage C: a meta-analysis of Asian population. Onco Targets Ther 2018;11:7883-94. [PMID: 30464535 DOI: 10.2147/OTT.S156844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zhu Q, Yu X, Zhou ZW, Luo M, Zhou C, He ZX, Chen Y, Zhou SF. A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor. J Cancer 2018;9:2061-71. [PMID: 29937924 DOI: 10.7150/jca.20822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Perkons NR, Stein EJ, Nwaezeapu C, Wildenberg JC, Saleh K, Itkin-Ofer R, Ackerman D, Soulen MC, Hunt SJ, Nadolski GJ, Gade TP. Electrolytic ablation enables cancer cell targeting through pH modulation. Commun Biol 2018;1:48. [PMID: 30271931 DOI: 10.1038/s42003-018-0047-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
21 Jung H, Kim BI, Cho YK, Jeon WK, Kim HJ, Hong HP. Complete cure of advanced hepatocellular carcinoma with right adrenal gland metastasis and portal vein thrombosis by multiple applications of an interdisciplinary therapy: case report with 8-year follow up. Clin Mol Hepatol 2018;24:424-9. [PMID: 29132204 DOI: 10.3350/cmh.2017.0032] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Wang W, Zhang M, Peng Y, He J. Ubiquitin Associated Protein 2-Like (UBAP2L) Overexpression in Patients with Hepatocellular Carcinoma and its Clinical Significance. Med Sci Monit 2017;23:4779-88. [PMID: 28981479 DOI: 10.12659/msm.907071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
23 Sun XJ, Xu GL. Overexpression of Acyl-CoA Ligase 4 (ACSL4) in Patients with Hepatocellular Carcinoma and its Prognosis. Med Sci Monit 2017;23:4343-50. [PMID: 28887439 DOI: 10.12659/msm.906639] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
24 Guo Q, Sui ZG, Xu W, Quan XH, Sun JL, Li X, Ji HY, Jing FB. Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells. Oncotarget 2017;8:72652-65. [PMID: 29069816 DOI: 10.18632/oncotarget.20194] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
25 . Selected Literature Watch. Cancer Biotherapy and Radiopharmaceuticals 2017;32:227-8. [DOI: 10.1089/cbr.2017.29000.lit] [Reference Citation Analysis]